Conjunctivitis, Bacterial clinical trials
The registry lists 40 studies for Conjunctivitis, Bacterial across more than 10 countries. 2 are recruiting or about to start. 39 of them are mainly about Conjunctivitis, Bacterial (how this is decided). Per ClinicalTrials.gov, last updated 2026-06-30. Counting its narrower condition Trachoma too: 79 studies, 5 open.
Get an email when these change. Save the Conjunctivitis, Bacterial studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Bausch & Lomb Incorporated (8) · Alcon Research (7) · Laboratorios Sophia S.A de C.V. (5) · Allergan (3) · Laboratoires Thea (2) · Merck Sharp & Dohme LLC (2) · Azidus Brasil (2) · NTC srl (1)
What is being tested here
Drugs under test in Conjunctivitis, Bacterial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 2 Conjunctivitis, Bacterial studies recruiting now, 2 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (50%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (50%) | 1 (50%) |
| 18 | 2 (100%) | 2 (100%) |
| 30 | 2 (100%) | 2 (100%) |
| 40 | 2 (100%) | 2 (100%) |
| 50 | 2 (100%) | 2 (100%) |
| 65 | 2 (100%) | 2 (100%) |
| 75 | 2 (100%) | 2 (100%) |
| 85 | 2 (100%) | 2 (100%) |
Across all 40 studies, recruiting or not: 20% stop at 75 or younger and 18% at 65; 70% take children; 0% are for women only and 0% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 40 of 40. search them.
- Safety and Efficacy of SUM-191 for Patients With Bacterial ConjunctivitisRecruitingNCT07565103Phase 1/21 country
- Efficacy of Fusidic Acid 1% in the Treatment of Bacterial ConjunctivitisRecruitingNCT06911424Phase 31 country
- Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial ConjunctivitisCompletedNCT05816070Phase 21 country
- Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy SubjectsCompletedNCT06363292Phase 11 country
- Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial ConjunctivitisCompletedNCT02432807Phase 31 country
- Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in AdultsCompletedNCT06616922Phase 24 countries
- Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.TerminatedNCT03696342Phase 31 country
- Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and PlaceboCompletedNCT03004924Phase 313 countries
- Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking OphthalmologistsCompletedNCT03987178Not applicable1 country
- Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy SubjectsCompletedNCT03519516Phase 11 country
- Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)CompletedNCT02980523Phase 21 country
- A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial ConjunctivitisCompletedNCT00518089Phase 32 countries
- Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers.WithdrawnNCT03698045Phase 11 country
- Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial ConjunctivitisCompletedNCT00759148Phase 3
- Local Pharmacokinetics of Azithromycin Eye Drops in Healthy VolunteersStatus unknownNCT03235141Phase 11 country
- AL-15469A for the Treatment of Bacterial ConjunctivitisCompletedNCT00332293Phase 31 country
- Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial ConjunctivitisCompletedNCT01877694Phase 21 country
- An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese PatientsCompletedNCT01573910Phase 31 country
- Clinical and Microbial Efficacy of ISV403 in Bacterial ConjunctivitisCompletedNCT00622908Phase 2
- A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial ConjunctivitisCompletedNCT00348348Phase 3
- A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.CompletedNCT00347932Phase 3
- Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and InfectionWithdrawnNCT01721694Phase 31 country
- Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.CompletedNCT01155999Phase 31 country
- Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial ConjunctivitisTerminatedNCT01740388Phase 31 country
- Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial ConjunctivitisTerminatedNCT01330355Phase 31 country
- Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)CompletedNCT00105469Phase 31 country
- Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)CompletedNCT00105534Phase 31 country
- Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to VehicleCompletedNCT01175590Phase 31 country
- Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial FloraCompletedNCT00312338Phase 41 country
- Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial ConjunctivitisCompletedNCT00972777Phase 2/31 country
- Systemic Pharmacokinetics of BOL-303224-ACompletedNCT00407589Phase 11 country
- Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial ConjunctivitisWithdrawnNCT01238783Phase 2
- A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial ConjunctivitisCompletedNCT00509873Phase 31 country
- A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial ConjunctivitisCompletedNCT00464438Phase 42 countries
- Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial ConjunctivitisStatus unknownNCT01227863Phase 31 country
- Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial ConjunctivitisStatus unknownNCT01227915Phase 31 country
- Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic TreatmentCompletedNCT00798577Phase 41 country
- AL-15469A for the Treatment of Bacterial ConjunctivitisCompletedNCT00331916Phase 31 country
- Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial ConjunctivitisCompletedNCT00565123Phase 2/31 country
- Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial ConjunctivitisCompletedNCT00357773Phase 3